|
1
|
Ingelfinger JR and Jarcho JA: Increase in
the incidence of diabetes and its implications. N Engl J Med.
376:1473–1474. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
da Rocha Fernandes J, Ogurtsova K,
Linnenkamp U, Guariguata L, Seuring T, Zhang P, Cavan D and
Makaroff LE: IDF Diabetes Atlas estimates of 2014 global health
expenditures on diabetes. Diabetes Res Clin Pract. 117:48–54.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Forbes JM and Cooper ME: Mechanisms of
diabetic complications. Physiol Rev. 93:137–188. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kato M, Castro NE and Natarajan R:
MicroRNAs: Potential mediators and biomarkers of diabetic
complications. Free Radic Biol Med. 64:85–94. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Reddy MA, Zhang E and Natarajan R:
Epigenetic mechanisms in diabetic complications and metabolic
memory. Diabetologia. 58:443–455. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pitocco D, Fuso L, Conte EG, Zaccardi F,
Condoluci C, Scavone G, Incalzi RA and Ghirlanda G: The diabetic
lung - a new target organ? Rev Diabet Stud. 9:23–35.
2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ahlqvist E, van Zuydam NR, Groop LC and
McCarthy MI: The genetics of diabetic complications. Nat Rev
Nephrol. 11:277–287. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Leung A and Natarajan R: Long noncoding
RNAs in diabetes and diabetic complications. Antioxid Redox Signal.
29:1064–1073. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Leung A, Amaram V and Natarajan R: Linking
diabetic vascular complications with LncRNAs. Vascul Pharmacol.
114:139–144. 2019.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kung CP and Murphy ME: The role of the p53
tumor suppressor in metabolism and diabetes. J Endocrinol.
231:R61–R75. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Grossi E, Sánchez Y and Huarte M:
Expanding the p53 regulatory network: LncRNAs take up the
challenge. Biochim Biophys Acta. 1859:200–208. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li L, Wang QF, Zou ML and He XA:
Overexpressed lncRNA ZEB1-AS1 promotes cell invasion and
angiogenesis through Wnt/β-catenin signaling in non-small cell lung
cancer. Int J Clin Exp Pathol. 10:3990–3997. 2017.
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-ΔΔC(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Labuschagne CF, Zani F and Vousden KH:
Control of metabolism by p53 - Cancer and beyond. Biochim Biophys
Acta Rev Cancer. 1870:32–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Peng J, Li X, Zhang D, Chen JK, Su Y,
Smith SB and Dong Z: Hyperglycemia, p53, and mitochondrial pathway
of apoptosis are involved in the susceptibility of diabetic models
to ischemic acute kidney injury. Kidney Int. 87:137–150.
2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gu J, Wang S, Guo H, Tan Y, Liang Y, Feng
A, Liu Q, Damodaran C, Zhang Z, Keller BB, et al: Inhibition of p53
prevents diabetic cardiomyopathy by preventing early-stage
apoptosis and cell senescence, reduced glycolysis, and impaired
angiogenesis. Cell Death Dis. 9(82)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang DY, Wang HJ and Tan YZ:
Wnt/β-catenin signaling induces the aging of mesenchymal stem cells
through the DNA damage response and the p53/p21 pathway. PLoS One.
6(e21397)2011.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gu Z, Tan W, Feng G, Meng Y, Shen B, Liu H
and Cheng C: Wnt/β-catenin signaling mediates the senescence of
bone marrow-mesenchymal stem cells from systemic lupus
erythematosus patients through the p53/p21 pathway. Mol Cell
Biochem. 387:27–37. 2014.PubMed/NCBI View Article : Google Scholar
|
